Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis to Collaborate with France's INRA

NEW YORK (GenomeWeb News) – French genome engineering company Cellectis said yesterday that it will collaborate with the French National Institute for Agricultural Research, or INRA, to investigate the use of Cellectis' technology in a range of applications.

Under the five-year, non-exclusive agreement, Cellectis and INRA will investigate the potential of a range of technologies in which Cellectis specializes, including reverse genetics, homologous recombination, and gene targeting, in applications such as cell biology and plant and animal biotechnology.

Cellectis and INRA said they plan to work together to disseminate results of their studies and transfer technology, particularly to small and medium companies in the agrofood, agriculture, and environment sectors.

The partnership covers genome engineering for all living species except humans, and will be overseen by a steering committee comprising three representatives from each organization, Cellectis said.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.